<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771587</url>
  </required_header>
  <id_info>
    <org_study_id>IMIMFTCL/AEDED</org_study_id>
    <nct_id>NCT02771587</nct_id>
  </id_info>
  <brief_title>Interaction of Alcohol With Energy Drinks</brief_title>
  <acronym>AEDED</acronym>
  <official_title>Effects of Alcohol and Energy Drinks on Driving Performance and Bleeding Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the project is to assess whether there is an interaction between the&#xD;
      effects of ethanol and energy drinks on driving performance.&#xD;
&#xD;
      Secondary objectives include: to evaluate subjective effects (drunkenness) after&#xD;
      administration of alcohol and energy drinks, to assess pharmacokinetics of alcohol, caffeine&#xD;
      and taurine after alcohol and energy drinks administration and to assess if there is an&#xD;
      increased risk of bleeding when both drinks are taken together.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consumption of energy drinks improve psychomotor performance and alertness. These drinks&#xD;
      contain mostly caffeine, taurine and vitamins. Its consumption associated with ethanol may&#xD;
      reduce feelings of drunkenness as the stimulant effects of caffeine could counteract the&#xD;
      depressing effects of ethanol on the central nervous system. Reducing the perception of&#xD;
      intoxication may predispose the intoxicated person to engage in risky behaviors such as&#xD;
      driving under the influence of ethanol and therefore can increase the risk of a traffic&#xD;
      accident. Furthermore, the combination of both beverages may increase the risk of bleeding in&#xD;
      case of injury as anticoagulant effects have been described for ethanol while antiplatelet&#xD;
      effects have been described for caffeine and taurine. A randomized clinical trial will be&#xD;
      performed in healthy volunteers administering 4 treatment conditions: alcohol+energy drink,&#xD;
      alcohol+placebo of energy drink, placebo of alcohol+energy drink and placebo of&#xD;
      alcohol+placebo of energy drink. A multiple dose will be administered separated by 1 hour.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tracking test performance</measure>
    <time_frame>From baseline till 4 hours after administration</time_frame>
    <description>The total time outside the road will be measured in the tracking test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in simple reaction time (SRT)</measure>
    <time_frame>From baseline till 4 hours after administration</time_frame>
    <description>Test will be performed using the computerized cognitive testing battery CANTAB and mean latency will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in movement estimation</measure>
    <time_frame>From baseline till 4 hours after administration</time_frame>
    <description>The lapse of time between actual and predicted time will be measured in a movement estimation task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in memory function</measure>
    <time_frame>From baseline till 4 hours after administration</time_frame>
    <description>The N-Back test will be performed with 2 different options: 0 back test and 2 back test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drunkenness</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Drunkenness will be measured using a visual analog scale (0-100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in drowsiness</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Drowsiness will be measured using a visual analog scale (0-100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in headache</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Headache will be measured using a visual analog scale (0-100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in palpitations</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Palpitations will be measured using a visual analog scale (0-100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Anxiety will be measured using a visual analog scale (0-100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective effects measured with Addiction Research Center Inventory (ARCI)</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Subjective effects of alcohol and caffeine will be measured using Addiction Research Center Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subjective effects measured with Biphasic alcohol effects scale (BAES)</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Subjective effects of alcohol will be measured using BAES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Systolic and diastolic blood pressure will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Heart rate will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oral temperature</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Oral temperature will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious and non-serious adverse events</measure>
    <time_frame>From inclusion till one week after the last experimental session</time_frame>
    <description>Collection of adverse effects spontaneously reported by the participants and/or observed by the investigators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC 0-8h) of ethanol blood concentrations</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Calculation of AUC of ethanol concentrations obtained baseline and 0.25, 0.50h , 0.75, 1, 1.50, 1.75, 2, 2.25, 2.5, 3, 4, 6 and 8h after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC 0-8h) of taurine blood concentrations</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Calculation of AUC of ethanol concentrations obtained baseline and 0.50,1, 1.50, 2, 4, 6 and 8h after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC 0-8h) of caffeine blood concentrations</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Calculation of AUC of ethanol concentrations obtained baseline and 0,25, 0.50,1, 1.50, 2, 3, 4, 6 and 8h after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC 0-8h) of ethanol breath air concentrations</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
    <description>Calculation of AUC of ethanol concentrations obtained baseline and 0.25, 0.50, 0.75,1, 1.50, 1.75, 2, 2.25, 2.5, 3, 4, 6 and 8h after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of taurine</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of ethanol</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of caffeine</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (tmax) of ethanol</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (tmax) of caffeine</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (tmax) of taurine</measure>
    <time_frame>From baseline till 8 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood coagulation prothrombin</measure>
    <time_frame>From baseline till 2 hours after administration</time_frame>
    <description>Prothrombin time (PT) and ratio will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood coagulation thromboplastin</measure>
    <time_frame>From baseline till 2 hours after administration</time_frame>
    <description>Activated partial thromboplastin time (APTT) and ratio will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation (function)</measure>
    <time_frame>From baseline till 2 hours after administration</time_frame>
    <description>Platelet function (PFA) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>From baseline till 2 hours after administration</time_frame>
    <description>Platelet count will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in willingness to drive</measure>
    <time_frame>From baseline till 6 hours after administration</time_frame>
    <description>Willingness to drive in 3 different situations will be measured by means of a visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Like the drug (drink)</measure>
    <time_frame>At the end of each experimental session</time_frame>
    <description>Drug liking will be measured using a visual analog scale (0-100 mm)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Alcohol-Related Disorders</condition>
  <condition>Drinking and Driving</condition>
  <arm_group>
    <arm_group_label>Alcohol and energy drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Energy drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.&#xD;
Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alcohol and energy drink</intervention_name>
    <description>Multiple oral dose of alcohol Multiple oral dose of energy drink</description>
    <arm_group_label>Alcohol and energy drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alcohol</intervention_name>
    <description>Multiple oral dose of alcohol</description>
    <arm_group_label>Alcohol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Energy drink</intervention_name>
    <description>Multiple oral dose of energy drink</description>
    <arm_group_label>Energy drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Non-active treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understand and accept the study's procedures and sign an informed consent form&#xD;
&#xD;
          -  No evidence of somatic or psychiatric disorders as per past medical history and&#xD;
             physical examination&#xD;
&#xD;
          -  EKG, blood and urine tests taken before entry into the study within the normal range.&#xD;
             Minor and transient abnormalities may be acceptable if, according to the Principal&#xD;
             Investigator's criterion and the state of the art, they are felt to have no clinical&#xD;
             relevance, entail no danger to the participant, and don't interfere with the product's&#xD;
             assessment. These abnormalities and their non-relevance must be specifically justified&#xD;
             in writing)&#xD;
&#xD;
          -  Body mass index (BMI=weight/heigth2) between 19 and 27 kg/m2, weight between 50 and&#xD;
             100 kg&#xD;
&#xD;
          -  For premenopausal females, a regular menstrual cycle of 26-32 days duration.&#xD;
&#xD;
          -  Social or recreational alcohol consumption of at least 1 unit per day (or its&#xD;
             equivalent [7 units] over the whole week) and having experienced drunkenness several&#xD;
             times&#xD;
&#xD;
          -  Regular consumption of beverages containing methylxanthines (at least 5 per week)&#xD;
&#xD;
          -  Consumption of energy drinks several times previously&#xD;
&#xD;
          -  Having a driving license&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of a preexisting condition (including gastrointestinal, liver, or kidney&#xD;
             disorders) that may alter the absorption, distribution, metabolism or excretion of the&#xD;
             drug or symptoms suggestive of drug-induced gastrointestinal irritation&#xD;
&#xD;
          -  Previous psychiatric disorders, alcoholism, abuse of prescription drugs or illegal&#xD;
             substances or regular consumption of psychoactive drugs&#xD;
&#xD;
          -  Having donated blood or having participated in this same study in the preceding 8&#xD;
             weeks, or having participated in any clinical trial with drugs in the preceding 12&#xD;
             weeks&#xD;
&#xD;
          -  Having had any somatic disease or having undergone major surgery in the 3 months prior&#xD;
             to inclusion in the trial&#xD;
&#xD;
          -  Individuals intolerant or having experienced a severe adverse reaction to alcohol or&#xD;
             energy drinks&#xD;
&#xD;
          -  Having regularly taken medication in the month before the trial, except for vitamins,&#xD;
             herb-based remedies, dietary supplements that if, according to the Principal&#xD;
             Investigator or his appointed collaborators' opinion, they pose no threat to the&#xD;
             subjects and they won't interfere with the study's objectives. Single doses of&#xD;
             symptomatic drugs taken during the week before the experimental session will not&#xD;
             constitute an exclusion criterion if it can be assumed that it has been completely&#xD;
             eliminated on the day of the experimental session&#xD;
&#xD;
          -  Smokers of &gt;5 cigarettes/day&#xD;
&#xD;
          -  Consumption of &gt;20 g/day of alcohol (females) or of &gt;40 g/day (males)&#xD;
&#xD;
          -  Daily consumption of more than 5 coffees, teas, cola drinks or other stimulant or&#xD;
             xanthine-containing beverages in the 3 months prior to inclusion in the study&#xD;
&#xD;
          -  Hepatitis B, hepatitis C or human immunodeficiency virus-positive individuals&#xD;
&#xD;
          -  Pregnant or lactating women, or those using hormonal or unreliable contraceptive&#xD;
             methods during the study period. Complete abstinence, intrauterine devices, double&#xD;
             barrier methods or a vasectomized sexual partner will be considered acceptable&#xD;
&#xD;
          -  Women with amenorrhea or suffering severe premenstrual syndrome&#xD;
&#xD;
          -  Individuals of Asian ascent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara Pérez Mañá, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMIM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IMIM</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc de Salut Mar-IMIM</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Parc de Salut Mar</investigator_affiliation>
    <investigator_full_name>Clara Pérez</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>alcohol</keyword>
  <keyword>energy drink</keyword>
  <keyword>coagulability</keyword>
  <keyword>caffeine</keyword>
  <keyword>taurine</keyword>
  <keyword>driving performance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

